The primary objective of RACE IT is to evaluate safety and feasibility of the combined application of preoperative radiation therapy with the PD-1 checkpoint-inhibitor Nivolumab followed by radical cystectomy in patients with locally advanced bladder cancer. Here, PDCD1 is linked to urinary bladder carcinoma.